Editors’ Picks, April 2024: Targeting Metabolism, KRAS, and More
April picks include metabolic interventions for acute myeloid leukemia, new inhibitors of KRAS signaling, and more.
April picks include metabolic interventions for acute myeloid leukemia, new inhibitors of KRAS signaling, and more.
Four of the 2023 GSITA recipients explain how the program has benefited their careers.
Event cochair Dr. Michael Caligiuri shares how attendees can form connections to take science from bench to market.
Lobular breast cancer accounts for 15% of all breast cancer cases, but it is understudied.
Researchers are examining the gut microbiome to find better ways to diagnose and manage colorectal cancer.
February’s selections include a modified Zika virus to treat cancer, insights into treatment resistance, and more.
This Trojan horse-like treatment strategy may help neutralize undruggable cancer drivers.
Researchers are finding early clinical success in developing more targeted treatments for bile duct cancer, also called cholangiocarcinoma.
Molecular profiling of individual cancers can determine who needs what treatment, and who can avoid certain treatments and complications....
Recent studies found awareness gaps about cancer prevention strategies such as screening and vaccination may reduce who benefits from...
January’s selections include disparities in genetic testing, updates from a breast cancer clinical trial, and more.